Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Ventricular rate adaptation: a novel, rapid, cellular-based in-vitro assay to identify proarrhythmic and torsadogenic compounds.

Green JR, Diaz GJ, Limberis JT, Houseman KA, Su Z, Martin RL, Cox BF, Kantor S, Gintant GA.

J Pharmacol Toxicol Methods. 2011 Jul-Aug;64(1):68-73. doi: 10.1016/j.vascn.2011.03.005. Epub 2011 Apr 2.

PMID:
21440075
2.

Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.

Guns PJ, Johnson DM, Weltens E, Lissens J.

J Pharmacol Toxicol Methods. 2012 Sep;66(2):125-34. doi: 10.1016/j.vascn.2012.03.007. Epub 2012 Apr 9.

PMID:
22516473
3.

A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).

Lu HR, Yan GX, Gallacher DJ.

J Pharmacol Toxicol Methods. 2013 Sep-Oct;68(2):250-9. doi: 10.1016/j.vascn.2013.01.003. Epub 2013 Jan 19.

PMID:
23337247
4.

Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk.

Gintant GA.

Pharmacol Ther. 2008 Aug;119(2):199-209. doi: 10.1016/j.pharmthera.2008.04.010. Epub 2008 Jun 18. Review.

PMID:
18621077
5.

Nonclinical proarrhythmia models: predicting Torsades de Pointes.

Lawrence CL, Pollard CE, Hammond TG, Valentin JP.

J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):46-59. Review.

PMID:
15975832
7.

Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.

Farkas AS, Nattel S.

Drugs. 2010 Mar 26;70(5):573-603. doi: 10.2165/11535230-000000000-00000. Review.

PMID:
20329805
8.
9.

Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit.

Lu HR, Vlaminckx E, Teisman A, Gallacher DJ.

J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):90-105.

PMID:
15978848
10.

A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.

Lawrence CL, Bridgland-Taylor MH, Pollard CE, Hammond TG, Valentin JP.

Br J Pharmacol. 2006 Dec;149(7):845-60. Epub 2006 Oct 9.

11.

Noninvasive cardiac activation imaging of ventricular arrhythmias during drug-induced QT prolongation in the rabbit heart.

Han C, Pogwizd SM, Killingsworth CR, Zhou Z, He B.

Heart Rhythm. 2013 Oct;10(10):1509-15. doi: 10.1016/j.hrthm.2013.06.010. Epub 2013 Jun 14.

12.

Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans.

Aubert M, Osterwalder R, Wagner B, Parrilla I, Cavero I, Doessegger L, Ertel EA.

Drug Saf. 2006;29(3):237-54.

PMID:
16524323
13.

The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.

Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BF.

J Cardiovasc Pharmacol. 2001 May;37(5):607-18.

PMID:
11336111
14.

Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.

Jacobson I, Carlsson L, Duker G.

J Pharmacol Toxicol Methods. 2011 Jan-Feb;63(1):40-6. doi: 10.1016/j.vascn.2010.04.010. Epub 2010 May 6.

PMID:
20451633
15.

Use of arterially perfused rabbit ventricular wedge in predicting arrhythmogenic potentials of drugs.

Chen X, Cordes JS, Bradley JA, Sun Z, Zhou J.

J Pharmacol Toxicol Methods. 2006 Nov-Dec;54(3):261-72. Epub 2006 Mar 6.

PMID:
16564186
16.

Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.

Davie C, Pierre-Valentin J, Pollard C, Standen N, Mitcheson J, Alexander P, Thong B.

J Cardiovasc Electrophysiol. 2004 Nov;15(11):1302-9.

PMID:
15574182
17.

A new preclinical biomarker for risk of Torsades de Pointes: drug-induced reduction of the cardiac electromechanical window.

Vargas HM.

Br J Pharmacol. 2010 Dec;161(7):1441-3. doi: 10.1111/j.1476-5381.2010.00980.x.

18.

Comparison of sensitivity of surrogate markers of drug-induced torsades de pointes in canine hearts.

Chiba K, Sugiyama A, Takasuna K, Hashimoto K.

Eur J Pharmacol. 2004 Oct 11;502(1-2):117-22.

PMID:
15464097
19.

An in vitro model for assessment of drug-induced torsade de pointes arrhythmia : effects of haloperidol and dofetilide on potential duration, repolarization inhomogeneities, and torsade de pointes arrhythmia.

Dhein S, Perlitz F, Mohr FW.

Naunyn Schmiedebergs Arch Pharmacol. 2008 Dec;378(6):631-44. doi: 10.1007/s00210-008-0329-0. Epub 2008 Jul 22.

PMID:
18648775
20.

Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.

Guo L, Dong Z, Guthrie H.

J Pharmacol Toxicol Methods. 2009 Sep-Oct;60(2):130-51. doi: 10.1016/j.vascn.2009.07.002. Epub 2009 Jul 18.

PMID:
19616638
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk